Michel Nussenzweig to Humans
This is a "connection" page, showing publications Michel Nussenzweig has written about Humans.
Connection Strength
0.171
-
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021 07; 595(7867):426-431.
Score: 0.008
-
Persistent cellular immunity to SARS-CoV-2 infection. J Exp Med. 2021 04 05; 218(4).
Score: 0.008
-
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021 04; 592(7855):616-622.
Score: 0.007
-
Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 03; 591(7851):639-644.
Score: 0.007
-
Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2021 01 20; 13(577).
Score: 0.007
-
All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature. 2020 10; 586(7830):501-502.
Score: 0.007
-
Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020 08; 584(7821):437-442.
Score: 0.007
-
HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. J Exp Med. 2019 06 03; 216(6):1301-1310.
Score: 0.007
-
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med. 2019 04; 25(4):547-553.
Score: 0.007
-
Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018 09; 561(7724):479-484.
Score: 0.006
-
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018 11; 24(11):1701-1707.
Score: 0.006
-
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med. 2018 09 03; 215(9):2311-2324.
Score: 0.006
-
Redemption for self-reactive antibodies. Science. 2018 04 13; 360(6385):152-153.
Score: 0.006
-
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. J Virol. 2018 03 01; 92(5).
Score: 0.006
-
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell. 2017 Aug 10; 170(4):637-648.e10.
Score: 0.006
-
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell. 2017 May 04; 169(4):597-609.e11.
Score: 0.006
-
HIV: Persistence through division. J Exp Med. 2017 04 03; 214(4):875-876.
Score: 0.006
-
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci Transl Med. 2017 01 18; 9(373).
Score: 0.006
-
Progress toward active or passive HIV-1 vaccination. J Exp Med. 2017 01; 214(1):3-16.
Score: 0.006
-
TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clin Chem. 2021 09 01; 67(9):1249-1258.
Score: 0.002
-
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 08 19; 6(62).
Score: 0.002
-
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Nat Commun. 2021 08 09; 12(1):4886.
Score: 0.002
-
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021 08 10; 54(8):1853-1868.e7.
Score: 0.002
-
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 2021 07 27; 36(4):109450.
Score: 0.002
-
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun. 2021 07 07; 12(1):4196.
Score: 0.002
-
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature. 2021 07; 595(7866):278-282.
Score: 0.002
-
Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021 06 10; 384(23):2212-2218.
Score: 0.002
-
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021 05; 593(7859):424-428.
Score: 0.002
-
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2021 03 01; 218(3).
Score: 0.002
-
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020 11 02; 217(11).
Score: 0.002
-
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020 10 28; 9.
Score: 0.002
-
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020 12; 588(7839):682-687.
Score: 0.002
-
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
Score: 0.002
-
Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
Score: 0.002
-
ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. Cell Rep Med. 2020 10 20; 1(7):100123.
Score: 0.002
-
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell. 2020 08 20; 182(4):828-842.e16.
Score: 0.002
-
We are here for you and ready to hear from you. J Exp Med. 2020 05 04; 217(5).
Score: 0.002
-
Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption. Proc Natl Acad Sci U S A. 2018 11 27; 115(48):E11341-E11348.
Score: 0.002
-
Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Cell Host Microbe. 2018 10 10; 24(4):579-592.e4.
Score: 0.002
-
A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat Med. 2018 05; 24(5):610-616.
Score: 0.002
-
Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nat Commun. 2018 03 28; 9(1):1251.
Score: 0.002
-
Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog. 2018 03; 14(3):e1006860.
Score: 0.002
-
Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med. 2017 Sep 04; 214(9):2573-2590.
Score: 0.001
-
Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. Elife. 2017 05 26; 6.
Score: 0.001
-
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017 Feb; 23(2):185-191.
Score: 0.001
-
Activation-induced cytidine deaminase in antibody diversification and chromosome translocation. Adv Cancer Res. 2012; 113:167-90.
Score: 0.001